Abstract. The 
various drugs at different doses (patients receiving identical compounds served as their own controls for the evaluation of dosage effects; duration of medication: 14 days at each dose). Oral administration of oestriol (1 and 2 mg daily; n = 6), oestriol (1 and 2 mg daily) + oestradiol-17\g=b\(2 and 4 mg daily; n = 8), oestradiol valerate (1, 2, 4 and 6 mg daily; n = 6), conjugated equine oestrogens (0.3 and 0.6 mg daily; n = 6), sodium oestrone sulphate (0.8 and 1.6 mg daily) + sodium equilin sulphate (0.2 and 0.4 mg daily; n = 6) and quinoestrol (25 \ g=m\ gdaily; n = 6) failed to alter TC-BC. However, ingestion of higher doses of conjugated equine oestrogens (0.9 and 1.25 mg daily; n = 5) and quinoestrol (50 \ g=m\ gdaily; n = 6) caused a significant rise (P < 0.01). Ethinyloestradiol was given orally as a reference substance and elicited an elevation of expected magnitude. Vaginal administration of dienoestrol cream (1 mg daily; n = 4) did not change TC-BC. These data indicate that the hepatotrophic effects of replacement oestrogens vary depending on the preparation and dosage selected for treatment.
Numerous oestrogen regimens are currently pre¬ scribed for the relief of climacteric symptoms.
They exert not only beneficial, but also potentially harmful effects, which extend beyond the primary target organs of the reproductive system. Despite widespread usage, replacement oestrogens remain poorly characterized in regard to their spectrum of biological properties; this is particularly true for their metabolic activities (Hammond et al. 1979 ).
As several undesirable side effects have been attri¬ buted to disturbances of hepatic protein synthesis, special attention must be paid to iatrogenic altera¬ tions of liver function (Geola et al. 1980 (Musa et al. 1965 (Musa et al. , 1967 . TC-BC was measured before and after each trial segment by a previously described combined adsorption-gel filtration technique (Schwartz & Hammerstein 1975 (Bernutz et al. 1979 ). This is not surprising in view of the observation made during pregnancy that transcortin only rises after serum oestradiol-17ß concentrations exceed 1300 pg/ml (Moore et al. 1978a ). While the low dose oral regimens fail to surpass the critical threshold levels, injections of comparable amounts of oestradiol, i.e. 5 mg per day, elicit a 2-fold elevation of transcortin (Katz & Kappas 1967) . This divergency of hepatotrophic effects is probably due to the increased bioavailability resulting from parenteral admini¬ stration of oestrogenic drugs (Schwartz et al. 1982 (Katz & Kappas 1967) .
Of the natural oestrogens investigated in this series, only conjugated equine oestrogens caused a significant transcortin rise when therapeutic doses greater than 0.6 mg daily were ingested. Similar dose-dependent alterations have previously been recorded after oral administration of up to 30 mg daily (Musa et al. 1965; Moore et al. 1978b; Geola et al. 1980 (Schwartz & Hammerstein 1974) .
Vaginal application of dienoestrol cream did not alter hepatic transcortin synthesis in the present study. It has been suggested that oestrogens given vaginally rather than orally circumvent the initial liver passage and, therefore, do not disturb hepatic function (Mishell et al. 1978) . Recently, however, it has been shown that vaginal administration per se does not facilitate a selective reduction of livermediated oestrogen effects (Schwartz et al. 1982 ).
Thus, the failure of intravaginal dienoestrol to increase transcortin is apparently due to the choice of compound and dose rather than the route of administration.
In conclusion, the present study demonstrates that natural oestrogens at doses commonly used for the amelioration of climacteric symptoms are less active than synthetic oestrogens in disturbing hepatic transcortin production. This should be considered when selecting an appropriate mode of replacement therapy, i.e. a regimen which supplies adequate oestrogen substitution, yet avoids unde¬ sirable side effects.
